Rethinking the Use of Biologics in Inflammatory Bowel Disease Patients With Malignancy: Insights From the Treatment of Immune Checkpoint Inhibitor-Induced Colitis.

IF 4.5 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Inflammatory Bowel Diseases Pub Date : 2025-06-13 DOI:10.1093/ibd/izaf065

Marco Vincenzo Lenti, Giovanni Santacroce, Antonio Di Sabatino

引用次数: 0

查看原文本刊更多论文

重新思考生物制剂在炎性肠病患者恶性肿瘤中的应用：来自免疫检查点抑制剂诱导结肠炎治疗的见解

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammatory Bowel Diseases 医学-胃肠肝病学

CiteScore

9.70

自引率

6.10%

发文量

462

审稿时长

1 months

期刊介绍： Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.